Structure-based Discovery of a new Protein-Aggregation Breaking Excipient

Andreas Tosstorff, Hristo Svilenov, Günther H.J. Peters, Pernille Harris, Gerhard Winter

Research output: Contribution to journalJournal articleResearchpeer-review

Abstract

Reducing the aggregation of proteins is of utmost interest to the pharmaceutical industry. Aggregated proteins are often less active and can cause severe immune reactions in the patient upon administration. At the same time the biopharmaceutical market is pushing for high concentration formulations and products that do not require refrigerated storage conditions. For a given protein, the only solution pH, ionic strength and concentration of a very limited number of excipients are the only parameters that can be varied to obtain a stable formulation. In this work, we present a structure-based approach to discover new molecules that successfully reduce the aggregation of proteins and apply the approach to the model protein Interferon-alpha-2a.
Original languageEnglish
JournalEuropean Journal of Pharmaceutics and Biopharmaceutics
Volume144
Pages (from-to)207-216
Number of pages10
ISSN0939-6411
DOIs
Publication statusPublished - 2019

Keywords

  • Interferon-alpha-2a
  • Virtual screen
  • Excipient
  • Protein aggregation
  • Protein formulation

Cite this

@article{18c6495e772e446ea1aa8515372c304a,
title = "Structure-based Discovery of a new Protein-Aggregation Breaking Excipient",
abstract = "Reducing the aggregation of proteins is of utmost interest to the pharmaceutical industry. Aggregated proteins are often less active and can cause severe immune reactions in the patient upon administration. At the same time the biopharmaceutical market is pushing for high concentration formulations and products that do not require refrigerated storage conditions. For a given protein, the only solution pH, ionic strength and concentration of a very limited number of excipients are the only parameters that can be varied to obtain a stable formulation. In this work, we present a structure-based approach to discover new molecules that successfully reduce the aggregation of proteins and apply the approach to the model protein Interferon-alpha-2a.",
keywords = "Interferon-alpha-2a, Virtual screen, Excipient, Protein aggregation, Protein formulation",
author = "Andreas Tosstorff and Hristo Svilenov and Peters, {G{\"u}nther H.J.} and Pernille Harris and Gerhard Winter",
year = "2019",
doi = "10.1016/j.ejpb.2019.09.010",
language = "English",
volume = "144",
pages = "207--216",
journal = "European Journal of Pharmaceutics and Biopharmaceutics",
issn = "0939-6411",
publisher = "Elsevier",

}

Structure-based Discovery of a new Protein-Aggregation Breaking Excipient. / Tosstorff, Andreas; Svilenov, Hristo; Peters, Günther H.J.; Harris, Pernille; Winter, Gerhard.

In: European Journal of Pharmaceutics and Biopharmaceutics, Vol. 144, 2019, p. 207-216.

Research output: Contribution to journalJournal articleResearchpeer-review

TY - JOUR

T1 - Structure-based Discovery of a new Protein-Aggregation Breaking Excipient

AU - Tosstorff, Andreas

AU - Svilenov, Hristo

AU - Peters, Günther H.J.

AU - Harris, Pernille

AU - Winter, Gerhard

PY - 2019

Y1 - 2019

N2 - Reducing the aggregation of proteins is of utmost interest to the pharmaceutical industry. Aggregated proteins are often less active and can cause severe immune reactions in the patient upon administration. At the same time the biopharmaceutical market is pushing for high concentration formulations and products that do not require refrigerated storage conditions. For a given protein, the only solution pH, ionic strength and concentration of a very limited number of excipients are the only parameters that can be varied to obtain a stable formulation. In this work, we present a structure-based approach to discover new molecules that successfully reduce the aggregation of proteins and apply the approach to the model protein Interferon-alpha-2a.

AB - Reducing the aggregation of proteins is of utmost interest to the pharmaceutical industry. Aggregated proteins are often less active and can cause severe immune reactions in the patient upon administration. At the same time the biopharmaceutical market is pushing for high concentration formulations and products that do not require refrigerated storage conditions. For a given protein, the only solution pH, ionic strength and concentration of a very limited number of excipients are the only parameters that can be varied to obtain a stable formulation. In this work, we present a structure-based approach to discover new molecules that successfully reduce the aggregation of proteins and apply the approach to the model protein Interferon-alpha-2a.

KW - Interferon-alpha-2a

KW - Virtual screen

KW - Excipient

KW - Protein aggregation

KW - Protein formulation

U2 - 10.1016/j.ejpb.2019.09.010

DO - 10.1016/j.ejpb.2019.09.010

M3 - Journal article

VL - 144

SP - 207

EP - 216

JO - European Journal of Pharmaceutics and Biopharmaceutics

JF - European Journal of Pharmaceutics and Biopharmaceutics

SN - 0939-6411

ER -